{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T02:42:03Z","timestamp":1791859323620,"version":"4.3.4"},"reference-count":116,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014434","name":"Polish National Agency for Academic Exchange","doi-asserted-by":"publisher","award":["PPN\/BIT\/2021\/1\/00056\/U\/00001"],"award-info":[{"award-number":["PPN\/BIT\/2021\/1\/00056\/U\/00001"]}],"id":[{"id":"10.13039\/501100014434","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomolecules"],"abstract":"<jats:p>The main protease (Mpro) of SARS-CoV-2 is an essential enzyme that plays a critical part in the virus\u2019s life cycle, making it a significant target for developing antiviral drugs. The inhibition of SARS-CoV-2 Mpro has emerged as a promising approach for developing therapeutic agents to treat COVID-19. This review explores the structure of the Mpro protein and analyzes the progress made in understanding protein\u2013ligand interactions of Mpro inhibitors. It focuses on binding kinetics, origin, and the chemical structure of these inhibitors. The review provides an in-depth analysis of recent clinical trials involving covalent and non-covalent inhibitors and emerging dual inhibitors targeting SARS-CoV-2 Mpro. By integrating findings from the literature and ongoing clinical trials, this review captures the current state of research into Mpro inhibitors, offering a comprehensive understanding of challenges and directions in their future development as anti-coronavirus agents. This information provides new insights and inspiration for medicinal chemists, paving the way for developing more effective Mpro inhibitors as novel COVID-19 therapies.<\/jats:p>","DOI":"10.3390\/biom14070797","type":"journal-article","created":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T14:40:50Z","timestamp":1720449650000},"page":"797","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["Inhibitors of SARS-CoV-2 Main Protease (Mpro) as Anti-Coronavirus Agents"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2510-7237","authenticated-orcid":false,"given":"Agnieszka","family":"Zag\u00f3rska","sequence":"first","affiliation":[{"name":"Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1448-9826","authenticated-orcid":false,"given":"Anna","family":"Czopek","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Fryc","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9731-908X","authenticated-orcid":false,"given":"Jakub","family":"Jo\u0144czyk","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Jagiellonian University Medical College, Medyczna 9, 30-688 Krak\u00f3w, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Naseer, S., Khalid, S., Parveen, S., Abbass, K., Song, H., and Achim, M.V. (2022). COVID-19 Outbreak: Impact on Global Economy. Front. Public Health, 10.","DOI":"10.3389\/fpubh.2022.1009393"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/s41591-023-02219-5","article-title":"Real-World COVID-19 Vaccine Effectiveness against the Omicron BA.2 Variant in a SARS-CoV-2 Infection-Naive Population","volume":"29","author":"Lau","year":"2023","journal-title":"Nat. Med."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1038\/s41541-024-00815-1","article-title":"SARS-CoV-2 Vaccination May Mitigate Dysregulation of IL-1\/IL-18 and Gastrointestinal Symptoms of the Post-COVID-19 Condition","volume":"9","author":"Fischer","year":"2024","journal-title":"NPJ Vaccines"},{"key":"ref_4","first-page":"903","article-title":"Oral Treatments for Outpatient COVID-19: Effectiveness and Value","volume":"28","author":"Beinfeld","year":"2022","journal-title":"J. Manag. Care Spec. Pharm."},{"key":"ref_5","first-page":"100694","article-title":"Efficacy and Safety of Paxlovid in Severe Adult Patients with SARS-CoV-2 Infection: A Multicenter Randomized Controlled Study","volume":"33","author":"Liu","year":"2023","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref_6","first-page":"CD015395","article-title":"Nirmatrelvir Combined with Ritonavir for Preventing and Treating COVID-19","volume":"2023","author":"Reis","year":"2023","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41573-023-00692-8","article-title":"Accelerating Antiviral Drug Discovery: Lessons from COVID-19","volume":"22","author":"Hall","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/s41579-024-01036-y","article-title":"COVID-19 Drug Discovery and Treatment Options","volume":"22","author":"Chan","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1038\/s41573-023-00672-y","article-title":"Therapeutic Strategies for COVID-19: Progress and Lessons Learned","volume":"22","author":"Li","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/emph\/eoac010","article-title":"Mutation Rate of SARS-CoV-2 and Emergence of Mutators during Experimental Evolution","volume":"10","author":"Amicone","year":"2022","journal-title":"Evol. Med. Public Health"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-2438-7_1","article-title":"Coronaviruses: An Overview of Their Replication and Pathogenesis","volume":"1282","author":"Fehr","year":"2015","journal-title":"Methods Mol. Biol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/s41579-023-00878-2","article-title":"The Evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1038\/s41586-023-06609-0","article-title":"Molecular Mechanisms of SARS-CoV-2 Resistance to Nirmatrelvir","volume":"622","author":"Duan","year":"2023","journal-title":"Nature"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41586-022-05514-2","article-title":"Multiple Pathways for SARS-CoV-2 Resistance to Nirmatrelvir","volume":"613","author":"Iketani","year":"2022","journal-title":"Nature"},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Noske, G.D., de Souza Silva, E., de Godoy, M.O., Dolci, I., Fernandes, R.S., Guido, R.V.C., Sj\u00f6, P., Oliva, G., and Godoy, A.S. (2023). Structural Basis of Nirmatrelvir and Ensitrelvir Activity against Naturally Occurring Polymorphisms of the SARS-CoV-2 Main Protease. J. Biol. Chem., 299.","DOI":"10.1016\/j.jbc.2023.103004"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s44259-023-00009-0","article-title":"Rapid Resistance Profiling of SARS-CoV-2 Protease Inhibitors","volume":"1","author":"Moghadasi","year":"2023","journal-title":"NPJ Antimicrob. Resistance"},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Ip, J.D., Chu, A.W.H., Chan, W.M., Leung, R.C.Y., Umer Abdullah, S.M., Sun, Y., and To, K.K.W. (2023). Global Prevalence of SARS-CoV-2 3CL Protease Mutations Associated with Nirmatrelvir or Ensitrelvir Resistance. eBioMedicine, 91.","DOI":"10.1016\/j.ebiom.2023.104559"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Hoang, H.D., Naeli, P., Alain, T., and Jafarnejad, S.M. (2023). Mechanisms of Impairment of Interferon Production by SARS-CoV-2. Biochem. Soc. Trans., 51.","DOI":"10.1042\/BST20221037"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"13190","DOI":"10.1073\/pnas.1835675100","article-title":"The Crystal Structures of Severe Acute Respiratory Syndrome Virus Main Protease and Its Complex with an Inhibitor","volume":"100","author":"Yang","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"eabe0751","DOI":"10.1126\/sciadv.abe0751","article-title":"Structure and Inhibition of the SARS-CoV-2 Main Protease Reveal Strategy for Developing Dual Inhibitors against Mpro and Cathepsin L","volume":"6","author":"Sacco","year":"2020","journal-title":"Sci. Adv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2591","DOI":"10.1021\/acsinfecdis.1c00237","article-title":"Recognition of Divergent Viral Substrates by the SARS-CoV-2 Main Protease","volume":"7","author":"MacDonald","year":"2021","journal-title":"ACS Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ho, B.L., Cheng, S.C., Shi, L., Wang, T.Y., Ho, K.I., and Chou, C.Y. (2015). Critical Assessment of the Important Residues Involved in the Dimerization and Catalysis of MERS Coronavirus Main Protease. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0144865"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Marzi, M., Vakil, M.K., Bahmanyar, M., and Zarenezhad, E. (2022). Paxlovid: Mechanism of Action, Synthesis, and in Silico Study. Biomed. Res. Int., 2022.","DOI":"10.1155\/2022\/7341493"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1080\/07391102.2020.1831610","article-title":"Cysteine Focused Covalent Inhibitors against the Main Protease of SARS-CoV-2","volume":"40","author":"Paul","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1021\/acsptsci.0c00216","article-title":"Identification of Inhibitors of SARS-CoV-2 3CL-Pro Enzymatic Activity Using a Small Molecule in Vitro Repurposing Screen","volume":"4","author":"Kuzikov","year":"2021","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20697","DOI":"10.1021\/jacs.1c08060","article-title":"Discovery of Di- and Trihaloacetamides as Covalent SARS-CoV-2 Main Protease Inhibitors with High Target Specificity","volume":"143","author":"Ma","year":"2021","journal-title":"J. Am. Chem. Soc."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Citarella, A., Scala, A., Piperno, A., and Micale, N. (2021). SARS-CoV-2 Mpro: A Potential Target for Peptidomimetics and Small-Molecule Inhibitors. Biomolecules, 11.","DOI":"10.3390\/biom11040607"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"8557","DOI":"10.2147\/IJGM.S332458","article-title":"Effectiveness of Remdesivir, Lopinavir\/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review","volume":"14","author":"Qomara","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejmech.2017.06.019","article-title":"Covalent Inhibitors Design and Discovery","volume":"138","author":"Kurian","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1177\/1087057116671509","article-title":"A Perspective on the Kinetics of Covalent and Irreversible Inhibition","volume":"22","author":"Strelow","year":"2017","journal-title":"SLAS Discov."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"108042","DOI":"10.1016\/j.jmgm.2021.108042","article-title":"Characterization of the Non-Covalent Interaction between the PF-07321332 Inhibitor and the SARS-CoV-2 Main Protease","volume":"110","author":"Macchiagodena","year":"2022","journal-title":"J. Mol. Graph. Model."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and Discovery of Its Inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"14702","DOI":"10.1021\/acs.jmedchem.1c01214","article-title":"Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies","volume":"64","author":"Ghosh","year":"2021","journal-title":"J. Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1021\/acs.jcim.1c00684","article-title":"Discovery of Novel Small-Molecule Inhibitors of SARS-CoV-2 Main Protease as Potential Leads for COVID-19 Treatment","volume":"61","author":"Manandhar","year":"2021","journal-title":"J. Chem. Inf. Model."},{"key":"ref_35","first-page":"1","article-title":"Feline Coronavirus Drug Inhibits the Main Protease of SARS-CoV-2 and Blocks Virus Replication","volume":"11","author":"Vuong","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_36","first-page":"1","article-title":"A New Generation Mpro Inhibitor with Potent Activity against SARS-CoV-2 Omicron Variants","volume":"8","author":"Huang","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abl4784","article-title":"An Oral SARS-CoV-2 Mpro Inhibitor Clinical Candidate for the Treatment of COVID-19","volume":"374","author":"Owen","year":"2021","journal-title":"Science"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.coviro.2021.04.006","article-title":"Considerations for the Discovery and Development of 3-Chymotrypsin-like Cysteine Protease Inhibitors Targeting SARS-CoV-2 Infection","volume":"49","author":"Vandyck","year":"2021","journal-title":"Curr. Opin. Virol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Kr\u00fcger, N., Kronenberger, T., Xie, H., Rocha, C., P\u00f6hlmann, S., Su, H., Xu, Y., Laufer, S.A., and Pillaiyar, T. (2023). Discovery of Polyphenolic Natural Products as SARS-CoV-2 Mpro Inhibitors for COVID-19. Pharmaceuticals, 16.","DOI":"10.3390\/ph16020190"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"123824","DOI":"10.1016\/j.talanta.2022.123824","article-title":"An Integrated Metabolomic and Proteomic Approach for the Identification of Covalent Inhibitors of the Main Protease (Mpro) of SARS-CoV-2 from Crude Natural Extracts","volume":"252","author":"Baron","year":"2023","journal-title":"Talanta"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e29208","DOI":"10.1002\/jmv.29208","article-title":"Discovery of the Covalent SARS-CoV-2 Mpro Inhibitors from Antiviral Herbs via Integrating Target-Based High-Throughput Screening and Chemoproteomic Approaches","volume":"95","author":"Zhang","year":"2023","journal-title":"J. Med. Virol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.bbrc.2020.08.086","article-title":"Andrographolide and Its Fluorescent Derivative Inhibit the Main Proteases of 2019-NCoV and SARS-CoV through Covalent Linkage","volume":"533","author":"Shi","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2200198","DOI":"10.1002\/minf.202200198","article-title":"Discovery of Natural-Derived Mpro Inhibitors as Therapeutic Candidates for COVID-19: Structure-Based Pharmacophore Screening Combined with QSAR Analysis","volume":"42","author":"Khanfar","year":"2023","journal-title":"Mol. Inf. Inform."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Samad, A., Ajmal, A., Mahmood, A., Khurshid, B., Li, P., Jan, S.M., Rehman, A.U., He, P., Abdalla, A.N., and Umair, M. (2023). Identification of Novel Inhibitors for SARS-CoV-2 as Therapeutic Options Using Machine Learning-Based Virtual Screening, Molecular Docking and MD Simulation. Front. Mol. Biosci., 10.","DOI":"10.3389\/fmolb.2023.1060076"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Pillai U, J., Cherian, L., Taunk, K., Iype, E., and Dutta, M. (2024). Identification of Antiviral Phytochemicals from Cranberry as Potential Inhibitors of SARS-CoV-2 Main Protease (Mpro). Int. J. Biol. Macromol., 261.","DOI":"10.1016\/j.ijbiomac.2024.129655"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1954","DOI":"10.1016\/j.drudis.2022.02.012","article-title":"Efficacy of Repurposed Antiviral Drugs: Lessons from COVID-19","volume":"27","author":"Martinez","year":"2022","journal-title":"Drug Discov. Today"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1021\/acs.jcim.3c00282","article-title":"Targeting SARS-CoV-2 Main Protease: A Successful Story Guided by an in Silico Drug Repurposing Approach","volume":"63","author":"Ambrosio","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"10012","DOI":"10.1073\/pnas.0403596101","article-title":"Small Molecules Targeting Severe Acute Respiratory Syndrome Human Coronavirus","volume":"101","author":"Wu","year":"2004","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"13237","DOI":"10.1039\/D4RA02029D","article-title":"Quinazolines and Thiazolidine-2,4-Dions as SARS-CoV-2 Inhibitors: Repurposing, in Silico Molecular Docking and Dynamics Simulation","volume":"14","author":"Sobhy","year":"2024","journal-title":"RSC Adv."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Xiao, B., Wu, S., Han, Y., Ren, L., Wang, J., Luan, X., Du, G., and She, Z. (2022). In Silico Screening of Minocycline as an Mpro Inhibitor and the Adjunctive Therapy Value for the Treatment of COVID-19. Res. Sq.","DOI":"10.21203\/rs.3.rs-1528733\/v1"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1007\/s12033-021-00299-7","article-title":"Cell-Based High-Throughput Screening Protocol for Discovering Antiviral Inhibitors Against SARS-CoV-2 Main Protease (3CLpro)","volume":"63","author":"Rothan","year":"2021","journal-title":"Mol. Biotechnol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1021\/acsptsci.0c00108","article-title":"Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-Throughput Screening","volume":"3","author":"Zhu","year":"2020","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s42003-022-03090-9","article-title":"Identification of SARS-CoV-2 Inhibitors Targeting Mpro and PLpro Using in-Cell-Protease Assay","volume":"5","author":"Narayanan","year":"2022","journal-title":"Commun. Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"101794","DOI":"10.1016\/j.xpro.2022.101794","article-title":"Protocol for High-Throughput Screening of SARS-CoV-2 Main Protease Inhibitors Using a Robust Fluorescence Polarization Assay","volume":"3","author":"Zhang","year":"2022","journal-title":"STAR Protoc."},{"key":"ref_55","first-page":"17","article-title":"High-Throughput Screening of SARS-CoV-2 Main and Papain-like Protease Inhibitors","volume":"14","author":"Zang","year":"2023","journal-title":"Protein Cell"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.slasd.2023.01.001","article-title":"High Throughput Screening for Drugs That Inhibit 3C-like Protease in SARS-CoV-2","volume":"28","author":"Smith","year":"2023","journal-title":"Slas Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1126\/science.abb4489","article-title":"Structure-Based Design of Antiviral Drug Candidates Targeting the SARS-CoV-2 Main Protease","volume":"368","author":"Dai","year":"2020","journal-title":"Science"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Lockbaum, G.J., Reyes, A.C., Lee, J.M., Tilvawala, R., Nalivaika, E.A., Ali, A., Yilmaz, N.K., Thompson, P.R., and Schiffer, C.A. (2021). Crystal Structure of SARS-CoV-2 Main Protease in Complex with the Non-Covalent Inhibitor Ml188. Viruses, 13.","DOI":"10.2210\/pdb7l0d\/pdb"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"40264","DOI":"10.1039\/D0RA06038K","article-title":"Pharmacophore-Based Approaches in the Rational Repurposing Technique for FDA Approved Drugs Targeting SARS-CoV-2 Mpro","volume":"10","author":"Balaramnavar","year":"2020","journal-title":"RSC Adv."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"472","DOI":"10.18006\/2021.9(4).472.480","article-title":"Fbdd: In-Silico Strategy to Inhibit Mpro Activity Using Drugs from Previous Outbreaks","volume":"9","author":"Trivedi","year":"2021","journal-title":"J. Exp. Biol. Agric. Sci."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Lee, J.Y., Kuo, C.J., Shin, J.S., Jung, E., Liang, P.H., and Jung, Y.S. (2021). Identification of Non-Covalent 3C-like Protease Inhibitors against Severe Acute Respiratory Syndrome Coronavirus-2 via Virtual Screening of a Korean Compound Library. Bioorganic Med. Chem. Lett., 42.","DOI":"10.1016\/j.bmcl.2021.128067"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"131378","DOI":"10.1016\/j.molstruc.2021.131378","article-title":"Computational Strategies towards Developing Novel SARS-CoV-2 Mpro Inhibitors against COVID-19","volume":"1247","author":"Luo","year":"2022","journal-title":"J. Mol. Struct."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Zhai, T., Zhang, F., Haider, S., Kraut, D., and Huang, Z. (2021). An Integrated Computational and Experimental Approach to Identifying Inhibitors for SARS-CoV-2 3CL Protease. Front. Mol. Biosci., 8.","DOI":"10.3389\/fmolb.2021.661424"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"105350","DOI":"10.1016\/j.antiviral.2022.105350","article-title":"Discovery of Novel SARS-CoV-2 Inhibitors Targeting the Main Protease Mpro by Virtual Screenings and Hit Optimization","volume":"204","author":"Mercorelli","year":"2022","journal-title":"Antivir. Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-022-06306-4","article-title":"Non-Covalent SARS-CoV-2 Mpro Inhibitors Developed from in Silico Screen Hits","volume":"12","author":"Rossetti","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Li, S., Wang, L., Meng, J., Zhao, Q., Zhang, L., and Liu, H. (2022). De Novo Design of Potential Inhibitors against SARS-CoV-2 Mpro. Comput. Biol. Med., 147.","DOI":"10.1016\/j.compbiomed.2022.105728"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1021\/acs.jcim.2c01377","article-title":"AI-Accelerated Design of Targeted Covalent Inhibitors for SARS-CoV-2","volume":"63","author":"Joshi","year":"2023","journal-title":"J. Chem. Inf. Model."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"15960","DOI":"10.1039\/D1SC05579H","article-title":"Automated Discovery of Noncovalent Inhibitors of SARS-CoV-2 Main Protease by Consensus Deep Docking of 40 Billion Small Molecules","volume":"12","author":"Gentile","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1021\/acscentsci.0c00229","article-title":"Deep Docking: A Deep Learning Platform for Augmentation of Structure Based Drug Discovery","volume":"6","author":"Gentile","year":"2020","journal-title":"ACS Cent. Sci."},{"key":"ref_70","first-page":"1","article-title":"Therapeutic Peptides: Current Applications and Future Directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"7438","DOI":"10.1021\/acs.jmedchem.2c00123","article-title":"Peptidomimetics: An Overview of Recent Medicinal Chemistry Efforts toward the Discovery of Novel Small Molecule Inhibitors","volume":"65","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Vagner, J., Qu, H., and Hruby, V.J. (2008). Peptidomimetics, a Synthetic Tool of Drug Discovery. Curr. Opin. Chem. Biol., 12.","DOI":"10.1016\/j.cbpa.2008.03.009"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1002\/anie.199416991","article-title":"Peptidomimetics\u2014Tailored Enzyme Inhibitors","volume":"33","author":"Gante","year":"1994","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1002\/anie.199112781","article-title":"Medicinal Chemistry in the Golden Age of Biology: Lessons from Steroid and Peptide Research","volume":"30","author":"Hirschmann","year":"1991","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev.bi.61.070192.002131","article-title":"Constrained Peptides: Models of Bioactive Peptides and Protein Substructures","volume":"61","author":"Rizo","year":"1992","journal-title":"Annu. Rev. Biochem."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41422-020-0356-z","article-title":"Boceprevir, GC-376, and Calpain Inhibitors II, XII Inhibit SARS-CoV-2 Viral Replication by Targeting the Viral Main Protease","volume":"30","author":"Ma","year":"2020","journal-title":"Cell Res."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Liu, Y., Lv, S., Peng, L., Xie, C., Gao, L., Sun, H., Lin, L., Ding, K., and Li, Z. (2021). Development and Application of Novel Electrophilic Warheads in Target Identification and Drug Discovery. Biochem. Pharmacol., 190.","DOI":"10.1016\/j.bcp.2021.114636"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"114999","DOI":"10.1016\/j.molliq.2020.114999","article-title":"Computational Study on Peptidomimetic Inhibitors against SARS-CoV-2 Main Protease","volume":"322","author":"Somboon","year":"2021","journal-title":"J. Mol. Liq."},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Shindo, N., and Ojida, A. (2021). Recent Progress in Covalent Warheads for in Vivo Targeting of Endogenous Proteins. Bioorganic Med. Chem., 47.","DOI":"10.1016\/j.bmc.2021.116386"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1021\/acs.jmedchem.9b01828","article-title":"\u03b1-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment","volume":"63","author":"Zhang","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2012.10.053","article-title":"Design, Synthesis and Crystallographic Analysis of Nitrile-Based Broad-Spectrum Peptidomimetic Inhibitors for Coronavirus 3C-like Proteases","volume":"59","author":"Chuck","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"6113","DOI":"10.1021\/jm0494873","article-title":"Synthesis and Evaluation of Keto-Glutamine Analogues as Potent Inhibitors of Severe Acute Respiratory Syndrome 3CLpro","volume":"47","author":"Jain","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.antiviral.2011.08.001","article-title":"Peptide Aldehyde Inhibitors Challenge the Substrate Specificity of the SARS-Coronavirus Main Protease","volume":"92","author":"Zhu","year":"2011","journal-title":"Antivir. Res."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/j.jmb.2005.09.004","article-title":"Crystal Structures of the Main Peptidase from the SARS Coronavirus Inhibited by a Substrate-like Aza-Peptide Epoxide","volume":"353","author":"Lee","year":"2005","journal-title":"J. Mol. Biol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"3212","DOI":"10.1021\/acs.jmedchem.7b00103","article-title":"Michael Acceptor-Based Peptidomimetic Inhibitor of Main Protease from Porcine Epidemic Diarrhea Virus","volume":"60","author":"Wang","year":"2017","journal-title":"J. Med. Chem."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.drudis.2020.01.015","article-title":"Recent Discovery and Development of Inhibitors Targeting Coronaviruses","volume":"25","author":"Pillaiyar","year":"2020","journal-title":"Drug Discov. Today"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1021\/acs.jmedchem.0c01063","article-title":"Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19","volume":"63","author":"Hoffman","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e07962","DOI":"10.1016\/j.heliyon.2021.e07962","article-title":"Telaprevir Is a Potential Drug for Repurposing against SARS-CoV-2: Computational and in Vitro Studies","volume":"7","author":"Mahmoud","year":"2021","journal-title":"Heliyon"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1039\/D0SC06195F","article-title":"Mechanism of Inhibition of SARS-CoV-2 Mpro by N3 Peptidyl Michael Acceptor Explained by QM\/MM Simulations and Design of New Derivatives with Tunable Chemical Reactivity","volume":"12","author":"Arafet","year":"2021","journal-title":"Chem. Sci."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1021\/acscatal.1c04661","article-title":"Impact of Warhead Modulations on the Covalent Inhibition of SARS-CoV-2 Mpro Explored by QM\/MM Simulations","volume":"12","author":"Arafet","year":"2022","journal-title":"ACS Catal."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1016\/j.chembiol.2021.05.018","article-title":"An Automatic Pipeline for the Design of Irreversible Derivatives Identifies a Potent SARS-CoV-2 Mpro Inhibitor","volume":"28","author":"Zaidman","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"115667","DOI":"10.1016\/j.ejmech.2023.115667","article-title":"Exploring Diverse Reactive Warheads for the Design of SARS-CoV-2 Main Protease Inhibitors","volume":"259","author":"Tan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/cpt.2603","article-title":"Innovative Randomized Phase I Study and Dosing Regimen Selection to Accelerate and Inform Pivotal COVID-19 Trial of Nirmatrelvir","volume":"112","author":"Singh","year":"2022","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with COVID-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1002\/cpdd.1174","article-title":"Safety, Tolerability, and Pharmacokinetics of Intravenous Doses of PF-07304814, a Phosphate Prodrug Protease Inhibitor for the Treatment of SARS-CoV-2, in Healthy Adult Participants","volume":"11","author":"Zhu","year":"2022","journal-title":"Clin. Pharmacol. Drug Dev."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"ofad355","DOI":"10.1093\/ofid\/ofad355","article-title":"Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Intravenous Infusions of PF-07304814 (Lufotrelvir) in Participants Hospitalized With COVID-19","volume":"10","author":"Robinson","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_97","unstructured":"Allerton, C.M.N., Arcari, J.T., Aschenbrenner, L.M., Avery, M., Bechle, B.M., Behzadi, M.A., Boras, B., Buzon, L.M., Cardin, R.D., and Catlin, N.R. (2023). A Second-Generation Oral SARS-CoV-2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19. J. Med. Chem., Online ahead of print."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"e01115-23","DOI":"10.1128\/aac.01115-23","article-title":"Phase I Study, and Dosing Regimen Selection for a Pivotal COVID-19 Trial of GST-HG171","volume":"68","author":"Zhang","year":"2024","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"102582","DOI":"10.1016\/j.eclinm.2024.102582","article-title":"Efficacy and Safety of GST-HG171 in Adult Patients with Mild to Moderate COVID-19: A Randomised, Double-Blind, Placebo-Controlled Phase 2\/3 Trial","volume":"71","author":"Lu","year":"2024","journal-title":"eClinicalMedicine"},{"key":"ref_100","first-page":"100835","article-title":"Efficacy and Safety of SIM0417 (SSD8432) plus Ritonavir for COVID-19 Treatment: A Randomised, Double-Blind, Placebo-Controlled, Phase 1b Trial","volume":"38","author":"Wang","year":"2023","journal-title":"Lancet Reg. Health West. Pac."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"106598","DOI":"10.1016\/j.ejps.2023.106598","article-title":"A First-in-Human Phase 1 Study of Simnotrelvir, a 3CL-like Protease Inhibitor for Treatment of COVID-19, in Healthy Adult Subjects","volume":"191","author":"Yang","year":"2023","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa2301425","article-title":"Oral Simnotrelvir for Adult Patients with Mild-to-Moderate COVID-19","volume":"390","author":"Cao","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"102359","DOI":"10.1016\/j.eclinm.2023.102359","article-title":"Leritrelvir for the Treatment of Mild or Moderate COVID-19 without Co-Administered Ritonavir: A Multicentre Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial","volume":"67","author":"Zhan","year":"2023","journal-title":"eClinicalMedicine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"6499","DOI":"10.1021\/acs.jmedchem.2c00117","article-title":"Discovery of S-217622, a Noncovalent Oral SARS-CoV-2 3CL Protease Inhibitor Clinical Candidate for Treating COVID-19","volume":"65","author":"Unoh","year":"2022","journal-title":"J. Med. Chem."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1007\/s40261-023-01309-z","article-title":"A Phase 1 Study of Ensitrelvir Fumaric Acid Tablets Evaluating the Safety, Pharmacokinetics and Food Effect in Healthy Adult Populations","volume":"43","author":"Shimizu","year":"2023","journal-title":"Clin. Drug Investig."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"E2354991","DOI":"10.1001\/jamanetworkopen.2023.54991","article-title":"Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial","volume":"7","author":"Yotsuyanagi","year":"2024","journal-title":"JAMA Netw. Open"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"17475198231184799","DOI":"10.1177\/17475198231184799","article-title":"Mpro-Targeted Anti-SARS-CoV-2 Inhibitor-Based Drugs","volume":"47","author":"She","year":"2023","journal-title":"J. Chem. Res."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1021\/acscentsci.2c01359","article-title":"Development of Highly Potent Noncovalent Inhibitors of SARS-CoV-2 3CLpro","volume":"9","author":"Hou","year":"2022","journal-title":"ACS Cent. Sci."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"115503","DOI":"10.1016\/j.ejmech.2023.115503","article-title":"Bench-to-Bedside: Innovation of Small Molecule Anti-SARS-CoV-2 Drugs in China","volume":"257","author":"Yang","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.medj.2023.12.004","article-title":"Olgotrelvir, a Dual Inhibitor of SARS-CoV-2 Mpro and Cathepsin L, as a Standalone Antiviral Oral Intervention Candidate for COVID-19","volume":"5","author":"Mao","year":"2024","journal-title":"Med"},{"key":"ref_111","unstructured":"(2024, June 24). Sorrento Announces Phase 3 Trial Met Primary Endpoint and Key Secondary Endpoint in Mild or Moderate COVID-19 Adult Patients Treated with Ovydso (Olgotrelvir), an Oral Mpro Inhibitor as a Standalone Treatment for COVID-19|BioSpace. Available online: https:\/\/www.biospace.com\/article\/releases\/sorrento-announces-phase-3-trial-met-primary-endpoint-and-key-secondary-endpoint-in-mild-or-moderate-covid-19-adult-patients-treated-with-ovydso-olgotrelvir-an-oral-mpro-inhibitor-as-a-standalone-treatment-for-covid-19\/."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1056\/NEJMc2205944","article-title":"Nirmatrelvir\u2013Ritonavir and Viral Load Rebound in COVID-19","volume":"387","author":"Anderson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_113","first-page":"3","article-title":"Individuals at Risk for Severe COVID-19 in Whom Ritonavir-Containing Therapies Are Contraindicated or May Lead to Interactions with Concomitant Medications: A Retrospective Analysis of German Health Insurance Claims Data","volume":"12","author":"Dykukha","year":"2023","journal-title":"Drugs Context"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.apsb.2023.08.004","article-title":"Medicinal Chemistry Strategies towards the Development of Non-Covalent SARS-CoV-2 Mpro Inhibitors","volume":"14","author":"Song","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"E33024","DOI":"10.1097\/MD.0000000000033024","article-title":"A Phase 2\/3 Study of S-217622 in Participants with SARS-CoV-2 Infection (Phase 3 Part)","volume":"102","author":"Yotsuyanagi","year":"2023","journal-title":"Medicine"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"EVIDoa2400026","DOI":"10.1056\/EVIDoa2400026","article-title":"Olgotrelvir as a Single-Agent Treatment of Nonhospitalized Patients with COVID-19","volume":"3","author":"Jiang","year":"2024","journal-title":"NEJM Evid."}],"container-title":["Biomolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/7\/797\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:10:16Z","timestamp":1760109016000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2218-273X\/14\/7\/797"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":116,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024,7]]}},"alternative-id":["biom14070797"],"URL":"https:\/\/doi.org\/10.3390\/biom14070797","relation":{},"ISSN":["2218-273X"],"issn-type":[{"value":"2218-273X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]}}}